Sign in

    Madhumita Yennawar • Leerink Partners

    Madhumita Yennawar's questions to Evolus Inc (EOLS) leadership

    Madhumita Yennawar's questions to Evolus Inc (EOLS) leadership • Q4 2024

    Question

    Madhumita Yennawar, on for Marc Goodman, asked for clarification on 2025 U.S. toxin market growth expectations and how Evolysse's in-vitro data on thermal and shear stress translates to clinical performance.

    Answer

    CFO Sandra Beaver clarified that while the market has historically been strong, the company's 2025 guidance prudently assumes a relatively flat filler market, offering potential upside. CMO Rui Avelar explained that the proprietary Cold-X technology better preserves HA's natural structure, leading to superior resistance to stress in lab tests. He stated this translated clinically to more correction and longer duration versus the control in studies, implying higher efficacy and longevity.

    Ask Fintool Equity Research AI

    Madhumita Yennawar's questions to Evolus Inc (EOLS) leadership • Q3 2024

    Question

    Madhumita Yennawar, on behalf of Marc Goodman at Leerink Partners, asked for an overview of current trends in the overall toxin market and for anecdotes on the resonance of Evolus's marketing and promotional efforts during the quarter.

    Answer

    President and CEO David Moatazedi stated that the toxin market is showing expected Q3 seasonality but remains resilient and growing compared to other aesthetic procedures. He noted that promotional activities were a continuation of the first half's strategy and expressed confidence in a strong Q4, which is seasonally the strongest period.

    Ask Fintool Equity Research AI